Bio-Techne (Bio-Techne) Net Margin %

: 10.08% (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Bio-Techne's Net Income for the three months ended in Dec. 2023 was $27 Mil. Bio-Techne's Revenue for the three months ended in Dec. 2023 was $273 Mil. Therefore, Bio-Techne's net margin for the quarter that ended in Dec. 2023 was 10.08%.

The historical rank and industry rank for Bio-Techne's Net Margin % or its related term are showing as below:

TECH' s Net Margin % Range Over the Past 10 Years
Min: 13.46 Med: 22.38 Max: 31.04
Current: 19.58

TECH's Net Margin % is ranked better than
88.79% of 1026 companies
in the Biotechnology industry
Industry Median: -163.69 vs TECH: 19.58

Bio-Techne Net Margin % Historical Data

The historical data trend for Bio-Techne's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Margin %

13.46

31.04

15.08

24.61

25.10

Bio-Techne Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																18.41	23.87	25.05	18.41	10.08

Competitive Comparison

For the Biotechnology subindustry, Bio-Techne's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Techne Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, Bio-Techne's Net Margin % distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Net Margin % falls into.

Bio-Techne Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Bio-Techne's Net Margin for the fiscal year that ended in Jun. 2023 is calculated as

Net Margin	=	Net Income (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	285.263	/	1136.702
	=	25.10 %

Bio-Techne's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	27.465	/	272.598
	=	10.08 %

Bio-Techne (NAS:TECH) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Bio-Techne Net Margin % Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne (Bio-Techne) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

TE1:Germany T1CH34:Brazil

Address

614 McKinley Place N.E., Minneapolis, MN, USA, 55413

Website

https://www.bio-techne.com

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Executives

Roeland Nusse	director	473 TENNESSEE, PALO ALTO CA 94306
William Geist	officer: PRESIDENT, PROTEIN SCIENCES	900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821
Charles R. Kummeth	director, officer: Chief Executive Officer	425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
Shane Bohnen	officer: SVP - General Counsel	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Brenda S. Furlow	officer: SVP - General Counsel	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
John L Higgins	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Robert V Baumgartner	director	5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416
Kim Kelderman	officer: Pres. Diagnostics & Genom	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Norman David Eansor	officer: SVP Biotech	8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
James Hippel	officer: Chief Financial Officer	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Joseph D Keegan	director	C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089
Alpna Seth	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Julie L Bushman	director	185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214
Rupert Vessey	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Randolph C Steer	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413